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Abstract
Background: Rotavirus vaccine was introduced in Kenya immunization program in July 2014. Pre-vaccine disease
burden estimates are important for assessing vaccine impact.
Methods: Children with acute gastroenteritis (AGE) (≥3 loose stools and/or ≥ 1 episode of unexplained vomiting
followed by loose stool within a 24-h period), hospitalized in Siaya County Referral Hospital (SCRH) from January
2010 through December 2013 were enrolled. Stool specimens were tested for rotavirus (RV) using an enzyme
immunoassay (EIA). Hospitalization rates were calculated using person-years of observation (PYO) from the Health
Demographic Surveillance System (HDSS) as a denominator, while adjusting for healthcare utilization at household
level and proportion of stool specimen collected from patients who met the case definition at the surveillance
hospital. Mortality rates were calculated using PYO as the denominator and number of deaths estimated using total
deaths in the HDSS, proportion of deaths attributed to diarrhoea by verbal autopsy (VA) and percent positive for
rotavirus AGE (RVAGE) hospitalizations.
Results: Of 7760 all-cause hospitalizations among children < 5 years of age, 3793 (49%) were included in the
analysis. Of these, 21% (805) had AGE; RV was detected in 143 (26%) of 541 stools tested. Among children < 5 years,
the estimated hospitalization rates per 100,000 PYO for AGE and RVAGE were 2413 and 429, respectively. Mortality
rate associated with AGE and RVAGE were 176 and 45 per 100,000 PYO, respectively.
Conclusion: AGE and RVAGE caused substantial health care burden (hospitalizations and deaths) before rotavirus
vaccine introduction in Kenya.
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Background
Rotavirus is the most common cause of vaccine-preventable
severe acute gastroenteritis (AGE) among infants and young
children worldwide [1, 2]. In 2013, RVAGE was estimated to
cause 215,000 global deaths among children < 5 years of
whom 2% (~ 4000) were from Kenya [3] alone. In Kenya,
RVAGE accounts for 19% (~ 9000) of annual hospitaliza-
tions among children < 5 years [4]. Two RV vaccines
Rotarix® (GlaxoSmithKline), and RotaTeq® (Merck & Co.),
are approved and recommended by the World Health
Organization (WHO) for global use [5]. Efficacy and effect-
iveness studies of these vaccines have shown significant re-
duction in AGE and RVAGE associated hospitalizations and
deaths among children < 5 years in both clinical trials and in
settings where they have been incorporated into the national
immunization programs [1, 6–10]. Consistent with data
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from Mexico [6] and Brazil [7, 11], African countries that
were early introducers of RV vaccines including Malawi
[10], Ghana [12], and Rwanda [13], have shown remarkable
declines in childhood morbidity and mortality associated
with AGE and RVAGE. Furthermore, the cost benefit of
these vaccines has equally been demonstrated [4, 7, 14]
.RV vaccine (Rotarix®) was introduced into the Kenya na-
tional immunization program in July 2014. Recent
population-based data on pre-vaccine disease rates are not
available in Kenya. However, such data are needed to
evaluate the impact of vaccination program and may help
county and national level governments, regional and glo-
bal decision makers with evidence needed to support in-
vestment in these vaccines.
We examined baseline rates of AGE and RVAGE specific
hospitalizations and deaths among children < 5 years in rural
western Kenya from January 1, 2010 to December 31, 2013
before RV vaccine introduction in Kenya.
Methods
Study site
Rotavirus surveillance and the Health Demographic Sur-
veillance System (HDSS) platform in our study setting
has been detailed elsewhere [15, 16]. In brief, the HDSS
site is located in Siaya County in rural western Kenya.
The HDSS is a longitudinal study that monitors births,
deaths, out and in-migrations and other demographics
of a defined population [16]. Our study was conducted
in Karemo HDSS area within Siaya county referral hos-
pital (SCRH) — the main regional referral hospital in
this setting.
Rotavirus surveillance and laboratory methods
As part of the African-based, World Health Organization
(WHO) coordinated RV rotavirus disease surveillance net-
work [17], we conducted hospital-based prospective sur-
veillance for RVAGE within the Kenya Medical Research
Institute (KEMRI) operated HDSS area in Karemo [15].
Children aged 0–59months residents of Karemo HDSS,
hospitalized at the in-patient department of SCRH with
AGE; defined as ≥3 looser than normal stools and/or ≥ 1
episode of unexplained vomiting followed by loose stool
within a 24-h period beginning within the 7 days before
seeking healthcare from January 1, 2010 to December 31,
2013 were eligible for enrolment. Trained health facility
recorders approached all eligible patient children, ex-
plained the study and administered a questionnaire on
demographics to their caretakers after obtaining informed
consent. A study clinician then examined these patients
and administered the standardized questionnaire to their
parent/caretaker to gather information about symptoms,
medical history, laboratory investigations, diagnosis, treat-
ment and outcome of hospitalization. A whole stool speci-
men was collected from each participant in a plastic
diaper from which at least 2ml of stool was scooped into
a specimen container using a sterile spatula within 48 h of
admission, transported on the same day to the enteric la-
boratory based at the KEMRI-CGHR, and finally tested
for rotavirus using a commercial enzyme immunoassay
(EIA) (Rotaclone Kit, Meridian Bioscience). A case of
RVAGE was defined as an AGE patient with a RV positive
stool specimen.
Data management
Details of the enrolment, testing and data management
have been described previously [15]. In brief, we linked
clinic data to laboratory results and to the longitudinal
data including cause of death from verbal autopsy (VA)
from the HDSS. During data collection, built-in software
in the electronic questionnaire with built-in checks and
controls ensured quality control. The linked data were
then uploaded and managed using a Microsoft SQL Ser-
ver 2008 database. Data were analysed using SAS version
9.4 (SAS Institute, Inc. Cary, North Carolina, USA).
Statistical analysis
Descriptive analysis for AGE and RVAGE
Proportion of admissions due to AGE was calculated by
dividing the number of AGE cases by the number of
all-cause admissions at SCRH who were residents of
Karemo HDSS during the study period. The proportion
of admissions that were associated with RVAGE was cal-
culated by dividing the number of RV positive stool
samples with the total samples collected and tested.
Positivity rates by month and patient characteristics
(age, gender, clinical features and illness outcome) were
calculated. These proportions were plotted by month to
show seasonality.
Analysis of RVAGE, disease severity and risk factors
The severity of RVAGE was assessed by using the 20-point
Vesikari score [18].A score of less than 11 was categorized
as mild while a score of 11 or more was classified as severe.
Bivariate comparison of the laboratory-confirmed RV posi-
tivity and patient characteristics and treatment outcomes
were evaluated using chi-square tests.
Incidence rates of hospitalization and mortality due to AGE
and RVAGE
We used person-years of observation (PYO) contributed
by all children aged less than 5 years residents of Karemo
region during the study period as the denominator. As de-
scribed previously [15], we calculated PYO by totaling
person-time for all children aged 0–59months who met
HDSS residency requirement during the 4-year study
period from 1st January 2010 or date of enrolment (if
after) until they exited or lost their HDSS residency status
through out-migration or death.
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The crude hospitalization rates were calculated by divid-
ing the total number of AGE and RVAGE hospitalizations
by the PYO contributed by children aged 0–59months for
the period that they met residency criteria for the HDSS.
We used two adjustments for the hospitalization rates.
First, to account for possible missed AGE cases, we di-
vided the crude rate of AGE and RVAGE by the propor-
tion of all in-patients who met the stool collection criteria,
whether a sample was collected or not.
The second adjustment accounted for children with AGE
or possibly RVAGE who did not reach or attend a sentinel
health care facility as reported from a population-based,
healthcare utilization and attitude surveys (HUAS) for diar-
rhoea—a separate household survey conducted within the
HDSS during the current RVAGE surveillance period
[19].The HUAS revealed that the frequencies of seeking
care for moderate-to-severe diarrhoea (MSD) from a hos-
pital were 69, 70, 67, 57 and 64% for children aged 0–5, 6–
11, 12–23, 24–59 and 0–59months, respectively (GEMS--
Kenya unpublished data). The 95% confidence intervals
(CI) were calculated around crude rates by using the PEPI
method [20]. Crude rates were then adjusted using Delta
method [21, 22]. The adjusted hospitalization rates were fi-
nally stratified and reported by age groups that included;
0–5, 6–11, 12–23, 24–59, 0–11 and 0–59months.
AGE and RVAGE mortality rates
Deaths were recorded at household level through regular in-
terviews of HDSS residents. Diarrhoea as a cause of death
was derived from Verbal autopsy (VA). The VA methodolo-
gies, coding and interpretation are described elsewhere [23,
24]. Upon the death of an HDSS resident, a trained
village-based reporter sent a notification to HDSS data team.
After a mourning period of at least 3 weeks, the interviewer
from the HDSS approached the most appropriate inter-
viewee who was closest to the deceased to administer a de-
tailed questionnaire focusing on the signs, symptoms and
medical history of the deceased. The VA data were collected
electronically, validated and processed using an InterVA pro-
gram, which is a probabilistic computer-based expert opinion
algorithm that determines the most probable cause of death
as described elsewhere [24]. We calculated the number of
deaths attributed to RV by multiplying the total under-five
deaths among HDSS residents in the study area by the pro-
portion of deaths attributable to diarrhoea by VA, and the
proportion of hospitalized AGE episodes attributable to RV
in each of the various age groups as described below.
Mortality rates associated with rotavirus gastroenteritis
were obtained by dividing the number of deaths attrib-
uted to rotavirus by the total PYO in each of the specific
age groups as described above.
Results
Enrolment profile and patient characteristics
During the study period, a total of 7760 all-cause hospitaliza-
tions among children < 5 years of age were recorded at the
SCRH paediatric ward, out of which 3793 were Karemo
HDSS resident population. Among the 3793 Karemo HDSS
resident children, 805 (21, 95%CI: 20–23) children were hos-
pitalized due to AGE (Fig. 1). RV-positivity among hospital-
ized children from Karemo with AGE was more pronounced
in infants (< 12months of age), then toddlers (12–23months
of age), and was least in school-age children (24–59months
of age) (Table 1). Characteristics of patients who had stool
specimens collected and those who did not have specimens
collected are shown in Table 2.
Of the 541 stool samples collected, 204 (38%) were
from infants aged 6–11months. There was no difference
in stool collection by gender. Furthermore, we did not
observe any statistical difference in rotavirus positivity in
male versus female patients among infants aged < 12
months ((69/211 [32.7%]) vs. (42/165 [25.4%]), OR =
1.42, p = 0.13),toddlers aged 12–23months ((9/61
[14.7%]) vs. (12/46 [26.1%]), OR = 0.49, p = 0.15), or in
children aged 24–59 months ((9/37 [24.3%]) vs. (2/21
[9.5%]), OR = 3.05, p = 0.18), respectively.
The overall annual proportion of rotavirus detection
ranged from 43/147 (29.3%) in 2010 to 21/95 (22.1%) in
2013 and the annual proportion of samples detected with
rotavirus did not differ significantly over the 4-year study
period. Rotavirus hospitalizations were seen throughout
the year over the surveillance period, but peaked from
January through March and around August–September
each year during study period (Fig. 2).
Compared with non-RVAGE cases, RVAGE cases were
younger ((median age = 8 Interquartile range [IQR] 5–
12) vs. 9 [IQR: 6–15] months; p < 0.032)), more likely to
present with vomiting ((126/143 (88.1%) vs. 297/397
(74.8%)), and more likely to be classified as severe by
Vesikari score (88/143 (61.5%) vs. 179/398 (44.9%),
p-value = 0.0007).(Table 3).The length of hospitalization
was similar for RVAGE compared to non-RVAGE (num-
ber of hospitalization days 4 [IQR] 3–6 vs. 4 [IQR] 3–6,
p-value = 0.564).
No of deaths attributable to RV ¼
Total under−five deaths among HDSS residents in study areað Þ
 proportion of deaths attributable to diarrheað Þ
 proportion of hospitalized AGE episodes attributable to RVð Þ
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Fig. 1 Flow diagram of Karemo DSS residents < 5 yrs. who were hospitalized and enrolled in the study from Siaya county referral hospital,
western Kenya 2010–2013
Table 1 Characteristics of children< 5 years hospitalized at SCRH with all cause morbidity, AGE and RVAGE, 2010—2013
Characteristics All Cause Hospitalizations
from Karemo DSS (N = 3793)
AGE Hospitalizations
(N = 805)
AGE specimen collected and tested
for RV ҂ (N = 541)
Proportion tested RV Positive
(N = 143)
n n (row %) n (row %) n (row %)
Sex
Male 2066 461 (22%) 309 (67%) 87 (28%)
Female 3793 344 (20%) 232 (67%) 56 (24%)
Year
2010 920 224 (24%) 147 (66%) 43 (29%)
2011 1335 313 (23%) 206 (66%) 53 (26%)
2012 822 147 (18%) 93 (63%) 26 (28%)
2013 716 121 (17%) 95 (79%) 21 (22%)
Age (Months)
0–5 536 205 (38%) 141 (69%) 45 (32%)
6–11 781 285 (36%) 204(72%) 57 (28%)
12–23 1110 205 (18%) 138 (67%) 30 (22%)
24–36 687 70 (10%) 40 (57%) 9 (23%)
37–59 679 40 (6%) 18 (45%) 2 (11%)
҂ 3 samples collected were not tested
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Hospitalization attributed to AGE in Karemo HDSS
The highest annual hospitalization rate (per 100,000
PYO) associated with AGE was observed in 2011
followed by 2010, 2012 and 2013 in descending order.
The annual incidence (per 100,000) of hospitalizations
due to all cause AGE was highest among infants and
children aged 6–11months remained most affected.
Hospitalization attributed to RVAGE among children < 5
years from Karemo HDSS
Incidence rates of RVAGE associated hospitalization was
highest among infants, particularly among those aged 6–11
months. We observed the highest RVAGE hospitalization
rate in 2011 followed by 2010, 2012 and 2013 in decreasing
order. Hospitalization rates for AGE and RVAGE are shown
in Table 4.
Mortality attributed to AGE and RVAGE
Discharge information was available for 531 (98%) of the
hospitalizations due to AGE of whom 33 (6.2%) died dur-
ing hospitalization. The case-fatality proportion among
RVAGE ((4.2%), [6/142]) compared to that observed from
non-RVAGE ((6.9%), [27/389]) cases was similar, p = 0.26.
The highest mortality rates of AGE and RVAGE were
observed among infants (< 12 months of age), and
remained most elevated among infants aged 6–11
months. Annual mortality rates associated with RVAGE
were stable between 2010 and 2011, but increased before
Table 2 Characteristics of Karemo resident children < 5 years hospitalized with AGE who had stool collected and those without
stool collected, Siaya County Referral Hospital, Western Kenya, 2010–2013
Characteristic Stool Sample Collected
(N = 544)
Stool Sample Not collected
(N = 261)
P-value
n (%) n (%)
Age
0–5 months 143 (26) 62 (24) 0.0034
6–11 months 204 (38) 81 (31)
12–23months 139 (26) 66 (25)
24–59months 58 (11) 52 (20)
Gender
Male 312 (57) 149 (57) 0.9
Female 232 (43) 112 (43)
Vesikari Score
Severe 268 (49) 93 (36) < 0.0001
Mild 276 (51) 168 (64)
Fig. 2 Rotavirus infection trends among hospitalized children < 5 years from Karemo DSS resident population seeking Care from Siaya County
Referral Hospital, western Kenya 2010–2013
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RV vaccine introduction, especially among children aged
6–11 months. Mortality rates attributed to AGE and
RVAGE are shown in Table 5.
Discussion
This study documents comprehensive, age-stratified
population-based hospitalization and mortality rates as-
sociated with AGE and RVAGE before introduction of
RV vaccines among Kenyan children < 5 years in a rural
community whose demographic and healthcare seeking
characteristics are well described [16, 19]. Unlike other
WHO rotavirus surveillance study sites in Africa, our
hospital-based surveillance site for rotavirus is unique
for a few reasons. First, it is supported by an ongoing
HDSS which monitors population denominators and
conducts verbal autopsy [16]. Second, our surveillance
hospital is the only regional public referral hospital for
the local HDSS and the only in-patient facility within
the HDSS, making our surveillance data representative
of the population as shown from our current data and as
previously observed [15]. Furthermore, the advantages of
a population-based incidence rate are two-fold. First, they
provide an opportunity to estimate number of people af-
fected by a disease. Second, they can help to project the
number of illness episodes that can be prevented with ef-
fectively known interventions such as vaccines [25].
Our 4-year study’s most important findings are that
before RV vaccine introduction in Kenya; approximately
90 and 60% of RVAGE hospitalized children were aged
< 2 years and < 1 year, respectively, and that hospitaliza-
tions and mortality associated with AGE and RVAGE
were highest among infants. Furthermore our data sug-
gests that children bearing the greatest burden of morbid-
ity and mortality associated with AGE and RVAGE were
infants aged 6–11months. This finding is similar to obser-
vations from neighboring Sudan where pre-RV vaccine
data indicates that 91 and 61% of rotavirus hospitaliza-
tions occurred before 2 years and 1 year respectively [26].
Table 3 The Vesikari scores for severity of illness among RVAGE and non- RVAGE hospitalized children <5 yrs. in Siaya County
Referral Hospital, western Kenya, 2010–2013
Variable Points assigned Rotavirus-positive Rotavirus-negative P-value
N = 143 N = 398
Duration of diarrhea (days)
1–4 1 119 (83) 281 (70%) 0.0089
5 2 4 (3%) 31 (8%)
> =6 3 20 (14%) 86 (22%)
Max no. diarrhea/24 h
1–3 1 41 (29%) 153 (38%) 0.1091
4–5 2 75 (52%) 177 (45%)
> =6 3 27 (19) 68 (17%)
Duration of vomiting (days) N = 126 N = 296
1 1 22 (15.4) 77 (19.4) 0.165
2 2 27 (18.9) 57 (14.4)
> =3 3 77 (53.8) 162 (40.9)
Max no. vomiting/24 h
1 1 8 (7%) 39 (13%) 0.1003
2–4 2 95 (75%) 214 (72%)
> =5 3 23 (18%) 43 (15%)
Fever
< 37.0 0 74 (52%) 196 (49%) 0.0435
37.1–38.4 1 58 (40%) 157 (40%)
38.5–38.9 2 8 (6%) 12 (3%)
> =39 3 3 (2%) 33 (8%)
Dehydration N = 55 N = 139
1–5% 2 48 (87%) 117 (84%) 0.5852
> =6% 3 7 (13%) 22 (16%)
Treatment* 2 143 (100%) 398 (100%) –
*All cases were treated in the ward
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Furthermore, our finding is consistent with observations
from the first 2 years of the current study [15], a study
conducted at the coastal region of Kenya [27], Global En-
teric Multicenter Study (GEMS) [2] and other studies con-
ducted in Europe [28] before introduction of RV vaccines.
Our observation that 21% of hospitalizations among chil-
dren < 5 years in the HDSS were due to AGE is similar to
23% reported previously from mid-term analysis of our
current study [15], 22% reported from Kilifi HDSS in
coastal region of Kenya [27], 21% from neighboring
Mwanza region in Tanzania [29], and 21% from Ethiopia
[30]. In addition, our finding that 26% of hospitalized
AGE case patients were infected with RV remains similar
to the rate of 27% reported from mid-term analysis of our
current surveillance data [15] and to 29% from Kilifi
HDSS at the Kenyan coast [27]. These observations sug-
gest that AGE and RVAGE burden in our setting is com-
parable to those from other settings in Kenya and
neighboring countries before RV vaccine introduction.
Our observation that rates of hospitalization due AGE
and RVAGE declined over the study period before vaccine
introduction may be associated with unknown non-RV
vaccine intervention factors. However, the proportion of
all deaths that were associated with AGE and RVAGE did
not follow the same pattern. Thus, these observed trends
are difficult to explain, though in part may reflect the ef-
fects of other interventions. Although widespread distri-
bution and use of zinc and ORS as part of devolved
government development efforts in Kenya has been de-
scribed [31] and may be a contributing factor to the ob-
served decline in diarrhea burden in this setting, such
argument remains speculative and prompts further inves-
tigation. This trend however is consistent with other ob-
servations from a recent community-based survey
conducted in this setting [19], and is not dissimilar to the
global trend of diarrhoea and rotavirus disease [3, 32].
Our data show that rotavirus was more commonly de-
tected among infants. Moreover, RVAGE presented with
more severe episodes than non-RVAGE as characterized
by severe dehydration, vomiting and low grade fever
—an observation similar to other previous studies [30,
33–35]. Rotavirus is the most common cause of severe
dehydrating diarrhoea and is the leading pathogen asso-
ciated with moderate-to-severe diarrhoea (MSD) [35], as
further reaffirmed by GEMS — the largest diarrhoea eti-
ology case-control study ever conducted in countries
representing the highest disease burden regions located
in Africa and Asia [2]. Severe dehydration caused by
diarrhoea in children is a major cause of preventable
morbidity and mortality in Kenya [31]. As commonly
observed in our setting and consistent with the care-
takers healthcare seeking trends in Kenya [19, 31], delay
in seeking care for childhood diarrhoea and reducing
amount of fluid and food intake during childhood AGE
illness can lead to severe disease. Our current study
found that case-fatality among RVAGE was not signifi-
cantly different from non-RVAGE cases, suggesting that
rotavirus may not be associated with mortality in hos-
pital based studies as shown from other studies [33, 36].
This finding supports the assumption that seeking care
for RVAGE from a health care facility enables access to
appropriate rehydration, which would then reduce the
risk of death from the disease.
Understanding seasonality of rotavirus can help for-
mulate hypothesis for assessing potential factors influen-
cing transmission and guide policy makers in deciding
on appropriate interventions and approaches that can
work in local settings for improving case management
during peak seasons [37]. For example, in settings such
as USA, rotavirus seasons have been observed to be de-
layed, shortened, and diminished [4, 38] after vaccine
introduction. In our current analysis, rotavirus detection
peaked in months which are locally known to be usually
warm and dry. Our current findings are consistent with
recent observations from Kenya [15, 33], and remains
similar to findings from other studies conducted in Bur-
kina Faso [37], Peru and Bangladesh [39] before rota-
virus vaccine introduction in those settings. Although
there is no unifying rotavirus seasonality pattern globally
[40], it’s spread by the faecal-oral route remains agree-
able [35], and even airborne or droplet transmission has
been postulated [41]. The later attribute potentially
makes the virus transmission route also to resemble that
of other non-enteric respiratory infectious diseases such
as measles [42].These observations suggests that a drop
in humidity and rainfall combined with dry soil could
potentially increase additional chance for transmission
through aerial contaminated faecal materials since sur-
vival of rotavirus may still be favored in such conditions
as described elsewhere [41, 43].
Treating RVAGE is expensive. In Kenya, it has been
estimated that rotavirus disease cost the national health-
care system $10.8 million each year, and that a 2-dose
rotavirus vaccine (RVV) series can avert ~ 2500 deaths,
~ 6000 hospitalizations and ~ 860,000 clinic visits with a
cost saving of $2.1 million annually [4].RV vaccines have
been shown to be effective in reducing the hospitaliza-
tions and death due to diarrhoea in children and the
protective effect potentially lasts through 2nd year of life
[1, 44].While the benefit of these vaccines has been doc-
umented in other African countries where they were in-
troduced ahead of Kenya, such as in South Africa [45],
Rwanda [3], Ghana [12],and Togo [46], population-level
benefits of RVV are yet to be demonstrated from Kenya.
A possible limitation of our current study is that many
rotavirus-associated fatalities are likely associated with
delay in healthcare seeking [5]. Furthermore, VA relies
on signs, symptoms and circumstances prior to death to
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assign cause of death which is subject to misclassifica-
tion error, and therefore the method as applied in our
current study may lead to over or under-estimation of
mortality [36]. Our methodology for estimating diar-
rhoea deaths attributable to rotavirus was based on the
following 3 assumptions: (i) that in the absence of treat-
ment, the hospitalized severe cases would not have sur-
vived; (ii) the treatment effect on survival of severe
diarrhoea is equal for rotavirus and non-rotavirus diar-
rhoea; and that (iii) the rotavirus attributable fraction of
severe diarrhoea observed in the sentinel hospital are
generalizable to the source population within each age
stratum as already described elsewhere [36]. Maintaining
caution when interpreting these estimates is important
since we recognize that such assumptions may affect the
validity and generalizability of the estimates to the gen-
eral population. However, since there are currently no
reliable data for the direct measurement of the propor-
tion of diarrhoea deaths that are attributable to rotavirus
[22, 36] especially in the high disease burden regions lo-
cated mostly in low-and middle income countries such
as in our setting [3], we believe our methodology re-
mains more reasonable, robust and applicable as recom-
mended by WHO [22, 36]. Moreover, our current
hospital surveillance data suggests agreeable representa-
tion of the source population consistent with previous
observations [15].
Conclusions
This study shows that AGE and RVAGE associated
hospitalization and deaths are high in this setting with
children aged 6–11 months bearing the greatest burden.
These findings support the introduction of a vaccine that
would potentially provide protection to young children
before the disease peaks at 6–11months of age in this
setting. While improvements in drinking water, sanita-
tion and hygiene can effectively prevent other forms of
diarrhoea, such interventions do not adequately prevent
the spread of rotavirus, thus leaving vaccines as the best
alternative in preventing AGE and RVAGE in settings
such as ours [5]. Continued surveillance will be import-
ant for measuring the impact of rotavirus vaccine intro-
duction in Kenya.
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